DEPOSIT AGREEMENT by and among Radiopharm Theranostics Limited as Issuer, DEUTSCHE BANK TRUST COMPANY AMERICAS as Depositary, AND THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES EVIDENCED BY AMERICAN DEPOSITARY RECEIPTS ISSUED...Deposit Agreement • February 13th, 2023 • Radiopharm Theranostics LTD • Pharmaceutical preparations • New York
DEPOSIT AGREEMENT, dated as of , 2023, by and among (i) Radiopharm Theranostics Limited, a company incorporated in the Commonwealth of Australia, with its principal executive office at 62 Lygon Street, Level 3, Carlton, Victoria, 3053, Australia (together with its successors, the “Company”), (ii) Deutsche Bank Trust Company Americas, an indirect wholly owned subsidiary of Deutsche Bank A.G., acting in its capacity as depositary, with its principal office at 1 Columbus Circle, New York, NY 10019, United States of America (the “Depositary”, which term shall include any successor depositary hereunder) and (iii) all Holders and Beneficial Owners of American Depositary Shares evidenced by American Depositary Receipts issued hereunder (all such capitalized terms as hereinafter defined).
Chief Executive Officer - Executive Service AgreementExecutive Service Agreement • February 13th, 2023 • Radiopharm Theranostics LTD • Pharmaceutical preparations • New South Wales
Radiopharm Theranostics (USA) Inc care of Vcorp Services, LLC. Located at 701 S. Carson Street, Suite 200, Carson City NV 89701, USA (Employer)
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • February 13th, 2023 • Radiopharm Theranostics LTD • Pharmaceutical preparations • England and Wales
LICENSE AMENDMENT AGREEMENTLicense Amendment Agreement • February 13th, 2023 • Radiopharm Theranostics LTD • Pharmaceutical preparations • Victoria
CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT WAS OMITTED BY MEANS OF MARKING SUCH INFORMATION WITH BRACKETS (“[***]”) BECAUSE THE IDENTIFIED CONFIDENTIAL INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR...Sublicense Agreement • February 13th, 2023 • Radiopharm Theranostics LTD • Pharmaceutical preparations
This Sublicense Agreement (hereinafter “Agreement”) entered into as of this 7th day of June, 2022 (“Effective Date”) by and between NeoIndicate LLC, an Ohio limited liability company, having a principal place of business at 52275 Griggs Rd., Wellington, OH 44090 (“NeoIndicate” or “Licensee”) and Radiopharm Theranostics Limited, an Australian corporation, having a principal place of business at Suite 1, Level 3, 62 Lygon St, Carlton South, VIC, 3053 Australia (“RAD” or “Sublicensee”).
Agreement for the Assignment of Intellectual PropertyAssignment of Intellectual Property • February 13th, 2023 • Radiopharm Theranostics LTD • Pharmaceutical preparations • Victoria
NanoMab (UK) Limited, a company incorporated and registered in England and Wales with a registered office at 720 Centennial Court Centennial Park, Elstree, Borehamwood, Hertfordshire WD6 3SY, United Kingdom (NanoMab UK); and
CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT WAS OMITTED BY MEANS OF MARKING SUCH INFORMATION WITH BRACKETS (“[***]”) BECAUSE THE IDENTIFIED CONFIDENTIAL INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR...Exclusive License Agreement • February 13th, 2023 • Radiopharm Theranostics LTD • Pharmaceutical preparations • Victoria
CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT WAS OMITTED BY MEANS OF MARKING SUCH INFORMATION WITH BRACKETS (“[***]”) BECAUSE THE IDENTIFIED CONFIDENTIAL INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR...Licence Agreement • February 13th, 2023 • Radiopharm Theranostics LTD • Pharmaceutical preparations • England and Wales
CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT WAS OMITTED BY MEANS OF MARKING SUCH INFORMATION WITH BRACKETS (“[***]”) BECAUSE THE IDENTIFIED CONFIDENTIAL INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR...Exclusive License Agreement • February 13th, 2023 • Radiopharm Theranostics LTD • Pharmaceutical preparations
This exclusive license agreement (“Agreement”) is made effective this 22nd day of March, 2022 (“Effective Date”), by and between The Regents of the University of California, a California public corporation, having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, CA 94607-5200 (“The Regents”), acting through The Technology Development Group of the University of California, Los Angeles (“UCLA”), located at 10889 Wilshire Boulevard, Suite 920, Los Angeles, CA 90095-7191, and Radiopharm Theranostics Limited. (“Licensee”), having a principal place of business at 101/50 McLachlan Avenue, Rushcutters Bay 2011 NSW, Australia.
CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT WAS OMITTED BY MEANS OF MARKING SUCH INFORMATION WITH BRACKETS (“[***]”) BECAUSE THE IDENTIFIED CONFIDENTIAL INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR...Exclusive License Agreement • February 13th, 2023 • Radiopharm Theranostics LTD • Pharmaceutical preparations
CANCER RESEARCH TECHNOLOGY LIMITED a company registered in England and Wales under number 1626049 with registered office at 2 Redman Place, London, E20 1JQ, England (CRT / Licensor); and
